PT  - JOURNAL ARTICLE
AU  - GEN HIRANO
AU  - AKITAKA MAKIYAMA
AU  - CHINATSU MAKIYAMA
AU  - TAITO ESAKI
AU  - HISANOBU ODA
AU  - KEITA UCHINO
AU  - MASATO KOMODA
AU  - RISA TANAKA
AU  - YUZO MATSUSHITA
AU  - KENJI MITSUGI
AU  - YOSHIHIRO SHIBATA
AU  - HOZUMI KUMAGAI
AU  - SHUJI ARITA
AU  - HIROSHI ARIYAMA
AU  - HITOSHI KUSABA
AU  - KOICHI AKASHI
AU  - EISHI BABA
TI  - Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan
DP  - 2015 Jan 01
TA  - Anticancer Research
PG  - 371--377
VI  - 35
IP  - 1
4099  - http://ar.iiarjournals.org/content/35/1/371.short
4100  - http://ar.iiarjournals.org/content/35/1/371.full
SO  - Anticancer Res2015 Jan 01; 35
AB  - Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib. Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined. Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%). Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.